MX2012009046A - Composiciones y metodos de inmunizacion. - Google Patents
Composiciones y metodos de inmunizacion.Info
- Publication number
- MX2012009046A MX2012009046A MX2012009046A MX2012009046A MX2012009046A MX 2012009046 A MX2012009046 A MX 2012009046A MX 2012009046 A MX2012009046 A MX 2012009046A MX 2012009046 A MX2012009046 A MX 2012009046A MX 2012009046 A MX2012009046 A MX 2012009046A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- virus
- compositions
- immunization compositions
- immunization
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0015—Combination vaccines based on measles-mumps-rubella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
- A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/099—Bordetella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
- C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20211—Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- C12N2760/20234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36211—Rubivirus, e.g. rubella virus
- C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención proporciona los métodos y composiciones para inducir en los mamíferos los anticuerpos de neutralización dirigidos a los serotipos del virus de dengue, virus de sarampión, virus de paperas, rubeola y/o virus VZV.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305114A EP2353609A1 (en) | 2010-02-04 | 2010-02-04 | Immunization compositions and methods |
PCT/EP2011/050800 WO2011095402A1 (en) | 2010-02-04 | 2011-01-21 | Immunization compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012009046A true MX2012009046A (es) | 2013-04-03 |
MX345555B MX345555B (es) | 2017-02-02 |
Family
ID=42224399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012009046A MX345555B (es) | 2010-02-04 | 2011-01-21 | Composiciones para inducir anticuerpos neutralizantes contra serotipos del virus del dengue. |
Country Status (11)
Country | Link |
---|---|
US (2) | US8697353B2 (es) |
EP (1) | EP2353609A1 (es) |
CN (1) | CN102740879B (es) |
AR (1) | AR080111A1 (es) |
AU (1) | AU2011212647B2 (es) |
BR (1) | BR112012019637A2 (es) |
HK (1) | HK1173657A1 (es) |
MX (1) | MX345555B (es) |
MY (1) | MY160639A (es) |
SG (1) | SG182833A1 (es) |
WO (1) | WO2011095402A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2882453B1 (en) | 2012-08-07 | 2021-01-06 | Massachusetts Institute of Technology | Anti-dengue virus antibodies and uses thereof |
US20150273035A1 (en) * | 2012-10-03 | 2015-10-01 | Sanofi Pasteur | Vaccination against japanese encephalitis, measles, mumps and rubella |
WO2014083194A1 (en) * | 2012-11-30 | 2014-06-05 | Sanofi Pasteur | Methods for inducing antibodies |
EP4183411A1 (en) | 2013-03-15 | 2023-05-24 | Takeda Vaccines, Inc. | Compositions and methods for dengue virus chimeric constructs in vaccines |
SG11201606163QA (en) | 2014-02-11 | 2016-08-30 | Massachusetts Inst Technology | Novel full spectrum anti-dengue antibody |
TW201620546A (zh) | 2014-09-02 | 2016-06-16 | 賽諾菲巴斯德公司 | 疫苗組合物 |
WO2017005654A1 (en) * | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue, diphtheria, tetanus, whooping cough (pertussis), polio, and haemophilus influenzae type b vaccination. |
WO2017005652A1 (en) | 2015-07-03 | 2017-01-12 | Sanofi Pasteur | Concomitant dengue and yellow fever vaccination |
US11690903B2 (en) | 2017-10-05 | 2023-07-04 | Sanofi Pasteur | Compositions for booster vaccination against dengue |
US11426461B2 (en) | 2018-09-05 | 2022-08-30 | Takeda Vaccines, Inc. | Methods for preventing dengue and hepatitis A |
SG11202102104SA (en) | 2018-09-05 | 2021-04-29 | Takeda Vaccines Inc | Dengue vaccine unit dose and administration thereof |
US11464815B2 (en) | 2018-09-05 | 2022-10-11 | Takeda Vaccines, Inc. | Dengue vaccine unit dose and administration thereof |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0832638B2 (ja) | 1989-05-25 | 1996-03-29 | カイロン コーポレイション | サブミクロン油滴乳剤を含んで成るアジュバント製剤 |
FR2649012B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Emulsions multiphasiques injectables |
FR2649013B1 (fr) | 1989-07-03 | 1991-10-25 | Seppic Sa | Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable |
GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
US6254873B1 (en) | 1995-04-17 | 2001-07-03 | The United States Of America As Represented By The Secretary Of The Army | Inactivated dengue virus vaccine |
WO1996040933A1 (en) | 1995-06-07 | 1996-12-19 | The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services | Infectious dengue 2 virus pdk-53 as quadravalent vaccine |
DE69841690D1 (de) | 1997-02-28 | 2010-07-08 | Acambis Inc | Chimäre Impfstoffe gegen Flaviviren |
GB9711990D0 (en) | 1997-06-11 | 1997-08-06 | Smithkline Beecham Biolog | Vaccine |
GB9718901D0 (en) | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
JP4426091B2 (ja) | 1997-09-05 | 2010-03-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | サポニンを含有する水中油型エマルション |
CA2365411A1 (en) | 1999-03-26 | 2000-10-05 | Walter Reed Army Institute Of Research | Attenuated dengue-2 virus vaccine |
EP1165131A2 (en) | 1999-03-26 | 2002-01-02 | Walter Reed Army Institute of Research | Attenuated dengue-1 virus vaccine |
JP2002540171A (ja) | 1999-03-26 | 2002-11-26 | ウォルター リード アーミー インスティテュート オブ リサーチ | 弱毒化デング熱4型ウイルスワクチン |
AU4178300A (en) | 1999-03-26 | 2000-10-16 | Walter Reed Army Institute Of Research | Attenuated dengue-3 virus vaccine |
EP2278012B1 (en) | 2000-02-16 | 2015-08-26 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Immunogenic Dengue 2 virus chimeras |
ATE412738T1 (de) | 2000-05-30 | 2008-11-15 | Univ Mahidol | Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen |
AT410634B (de) | 2001-02-21 | 2003-06-25 | Franz X Dr Heinz | Attenuierte lebendimpfstoffe |
CA3060687C (en) | 2001-05-22 | 2021-05-04 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
KR20040004642A (ko) | 2001-05-23 | 2004-01-13 | 덴드레온 샌 디에고 엘엘씨 | 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 |
CN1551782A (zh) | 2001-06-01 | 2004-12-01 | ��������ķ������ | 嵌合黄病毒载体 |
AU2003239932A1 (en) | 2002-05-31 | 2003-12-19 | Acambis, Inc. | Tetravalent dengue vaccines |
JP5059407B2 (ja) | 2004-06-25 | 2012-10-24 | 国立大学法人北海道大学 | ゲル、その製造方法、吸水性樹脂、潤滑材及び細胞培養用基材 |
WO2006001513A1 (ja) | 2004-06-25 | 2006-01-05 | Canon Kabushiki Kaisha | 水性インク、インクタンク、インクジェット記録装置、インクジェット記録方法、及びインクジェット記録画像 |
FR2906724B1 (fr) * | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
FR2909286B1 (fr) * | 2006-12-01 | 2012-06-08 | Sanofi Pasteur | Methode d'immunisation contre les 4 serotypes de la dengue |
-
2010
- 2010-02-04 EP EP10305114A patent/EP2353609A1/en not_active Withdrawn
-
2011
- 2011-01-21 BR BR112012019637A patent/BR112012019637A2/pt not_active Application Discontinuation
- 2011-01-21 MY MYPI2012003427A patent/MY160639A/en unknown
- 2011-01-21 SG SG2012056925A patent/SG182833A1/en unknown
- 2011-01-21 CN CN201180008304.7A patent/CN102740879B/zh active Active
- 2011-01-21 AU AU2011212647A patent/AU2011212647B2/en active Active
- 2011-01-21 WO PCT/EP2011/050800 patent/WO2011095402A1/en active Application Filing
- 2011-01-21 MX MX2012009046A patent/MX345555B/es active IP Right Grant
- 2011-02-01 US US13/019,243 patent/US8697353B2/en active Active
- 2011-02-02 AR ARP110100348A patent/AR080111A1/es unknown
-
2013
- 2013-01-17 HK HK13100746.2A patent/HK1173657A1/zh unknown
-
2014
- 2014-04-14 US US14/251,970 patent/US10143741B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
WO2011095402A1 (en) | 2011-08-11 |
CN102740879B (zh) | 2016-05-04 |
US20110189226A1 (en) | 2011-08-04 |
HK1173657A1 (zh) | 2013-05-24 |
SG182833A1 (en) | 2012-09-27 |
AR080111A1 (es) | 2012-03-14 |
US8697353B2 (en) | 2014-04-15 |
MX345555B (es) | 2017-02-02 |
US10143741B2 (en) | 2018-12-04 |
AU2011212647A1 (en) | 2012-08-23 |
CN102740879A (zh) | 2012-10-17 |
EP2353609A1 (en) | 2011-08-10 |
MY160639A (en) | 2017-03-15 |
US20140220073A1 (en) | 2014-08-07 |
BR112012019637A2 (pt) | 2016-05-03 |
AU2011212647B2 (en) | 2015-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MY160639A (en) | Immunization compositions and methods | |
MX2018016021A (es) | Composiciones y metodos que comprenden variante de enzima lipolitica. | |
MX371497B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica. | |
JO3118B1 (ar) | تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX352324B (es) | Vacunas multivalentes de nanovehiculos sinteticos. | |
PH12014501427B1 (en) | Anti-phf-tau antibodies and their uses | |
MX345909B (es) | Anticuerpos anti-fgfr3 y métodos que los utilizan. | |
MX2013009175A (es) | Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas. | |
WO2013054199A3 (en) | Cmv antigens and uses thereof | |
MX2012005782A (es) | Procedimientos, composiciones y kits de liofilizacion. | |
MX342270B (es) | ANTICUERPO NEUTRALIZANTE DE LA INTEGRINA AVß8. | |
PH12014502628B1 (en) | Compositions and methods related to the prevention and treatment of rabies infection | |
MX2013001473A (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
MX2014010754A (es) | Composiciones que comprenden inmunoglobulinas de tipo secretor. | |
MX2013002960A (es) | Composiciones de anticuerpo y metodos de uso. | |
GEP20197052B (en) | Hyr1-derived compositions and methods of treatment using same | |
MY168926A (en) | Treated silicas and metal silicates for improved cleaning in dentifrice | |
WO2014184683A3 (en) | Compositions and methods for targeting antigen-presenting cells | |
MX346501B (es) | Metodos, composiciones y kits para la determinacion del virus de la hepatitis a. | |
MX2014006597A (es) | Polimeros de condensacion de acido mandelico. | |
MY171384A (en) | Composition and methods related to the prevention and treatment of rabies infection | |
TN2011000041A1 (en) | Compositions and methods for antibodies targeting complement protein c5 | |
WO2011116262A3 (en) | Compositions and methods for diagnosing and treating urinary tract infections |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |